Receptor Ledger · POMC & MC1R–MC5R Biology Dispatch 02 · Origin & Switchboard

One precursor gene, one four-amino-acid key, five very different organs

Every clinical advance and every off-target effect in melanocortin pharmacology begins with an evolutionary constraint: five related cell-surface switches recognize closely overlapping sequences cleaved from one precursor protein.

Elevated midday photograph of a carved pale travertine limestone desert irrigation sluice dividing a single sunlit water channel cleanly into five parallel stone runnels across dry desert-ochre clay.
Field Record 04 · Five Channels A single precursor protein (POMC) yields the melanocortin ligands that signal across five receptor channels (MC1R through MC5R), explaining why nonselective peptides spill across organs.

How sunlight triggers the POMC precursor

Natural suntanning is a stress-response cascade, not a benign cosmetic glow. In 2007, biochemical and genetic experiments by Rutao Cui, David Fisher, and colleagues showed that ultraviolet-induced pigmentation requires keratinocytes (outer skin cells) to secrete alpha-melanocyte-stimulating hormone (α-MSH) under the direct control of the tumor-suppressor protein p53. When UV strikes skin DNA, p53 activates transcription of the pro-opiomelanocortin (POMC) gene; in knockout mice lacking p53, the UV-tanning response disappears. The same pathway also produces β-endorphin, which the authors note may contribute to sun-seeking behavior.

POMC acts as a biological precursor cut sequentially into distinct hormone families. As Heiko Krude and colleagues summarized in 1998, sequential cleavage of pre-pro-opiomelanocortin generates the melanocortin peptides—adrenocorticotropic hormone (ACTH) and alpha-, beta-, and gamma-MSH—as well as the opioid-receptor ligand beta-endorphin. Whereas β-endorphin signals through opioid receptors, the cleaved melanocortin peptides dock onto five closely related G protein-coupled receptors (GPCRs)—cell-surface proteins that thread across a cell membrane seven times to relay external chemical signals into intracellular messengers such as cyclic AMP.

Diagram tracing POMC precursor cleavage into alpha, beta, and gamma MSH carrying the His-Phe-Arg-Trp core (signaling through MC1R, MC3R, MC4R, and MC5R) and ACTH, which stimulates all five melanocortin receptors and is the sole endogenous ligand for MC2R requiring its first 17 amino acids, noting 38% to 60% receptor sequence identity.
Figure 2 · One Precursor, Five Targets. Cleaved α-, β-, and γ-MSH signal across MC1R, MC3R, MC4R, and MC5R; ACTH stimulates all five receptors and is the sole endogenous agonist for adrenal MC2R, requiring its first 17 amino acids. Sources: Krude (1998), Yang (2011), Cai & Hruby (2016), Yuan & Tao (2022).

Why receptor selectivity is chemically difficult

After the first melanocortin receptor genes were cloned by Mountjoy, Cone, and colleagues in 1992, sequence comparisons exposed why synthetic peptides cross between subtypes. Melanocortin receptors are the smallest G protein-coupled receptors known, and human subtypes share 38% to 60% sequence identity—highest between MC4R and MC5R (60%), 45% between MC3R and MC1R or MC2R, and lowest between MC2R and MC4R (38%).

Every natural melanocortin agonist derived from POMC carries the evolutionarily conserved four-amino-acid sequence His-Phe-Arg-Trp. Functional mapping reviewed by Yuan and Tao (2022) distinguishes each receptor's activation requirement: His-Phe-Arg-Trp is the minimal MSH sequence required for MC1R, MC3R, and MC5R activation, three amino acids (Phe-Arg-Trp) suffice in MSH for MC4R, and the first 17 amino acids of ACTH are required for MC2R. Because four pockets recognize that short motif, chemists have faced considerable difficulty developing highly selective ligands.

Receptor-by-receptor accounting: MC1R through MC5R

EC50 potency at human receptors across the switchboard

Pharmacologists compare receptor activity using EC50—the concentration producing half-maximal activation in in vitro assays at human melanocortin receptors, reported in nanomolar (nM), where a lower number means higher potency. In vitro receptor EC50 values do not measure blood-brain-barrier entry, implant release kinetics, or clinical exposure, but they expose the selectivity profile of each peptide.

Logarithmic dot plot of EC50 at human melanocortin receptors in nanomolar across MC1R, MC3R, MC4R, and MC5R from Yuan and Tao 2022 Table 3, showing Melanotan II and afamelanotide clustered at subnanomolar potency across multiple receptors while setmelanotide shifts sharply to 1600 nM at MC5R.
Figure 3 · EC50 at Human Receptors (Log Scale). Lower EC50 values toward the left reflect stronger activation at human melanocortin receptors. Data compiled from Table 3 of Yuan & Tao (2022) (primary assay set from Kievit et al., 2013; *bremelanotide from Durek et al., 2018, where MC5R was not reported).
EC50 Potency at Human Melanocortin Receptors (Yuan & Tao, 2022 Table 3; Kievit et al., 2013 & Durek et al., 2018*)
Peptide MC1R (nM) MC3R (nM) MC4R (nM) MC5R (nM)
Native α-MSH 1.01 1.04 4.7 10.5
Afamelanotide (NDP-MSH) 0.462 0.109 0.075 0.253
Bremelanotide* 0.095 2.4 0.25 Not reported
Setmelanotide 5.8 5.3 0.27 1600
Melanotan II 0.2 0.51 0.05 5.33

Two contrasts stand out in Yuan and Tao's Table 3 (compiling Kievit et al., 2013, and *Durek et al., 2018 for bremelanotide). First, Melanotan II acts as a nonselective agonist with nanomolar to subnanomolar potency across MC1R (0.2 nM), MC3R (0.51 nM), MC4R (0.05 nM), and MC5R (5.33 nM). Second, even linear afamelanotide shows subnanomolar potency at MC3R and MC4R in human-receptor assays—underscoring why clinical development relies on formulation control and tissue access as well as receptor affinity.

Natural brakes, allosteric pockets, and biased signaling

Unlike many hormone receptors, melanocortins exhibit high basal activity. As King and colleagues note, MCRs 1, 3, 4, and 5 maintain high constitutive (ligand-independent) activity, allowing antagonists to decrease basal cyclic AMP levels. Two endogenous proteins fill that role: agouti signaling protein (ASIP) selectively antagonizes MC1R and MC4R, while agouti-related protein (AgRP) selectively antagonizes MC3R and MC4R.

As Yingkui Yang (2011) defines the binding geometry, endogenous agonists bind the orthosteric site—the receptor area where natural ligands dock—whereas an allosteric site is distinct from that endogenous binding site. Modern MC4R drug design also examines biased signaling: MC4R can couple to three major G-protein families (Gs, Gi/o, and Gq). Earlier clinical MC4R obesity candidates failed in human trials despite preclinical efficacy due to poor efficacy and side effects. By contrast, setmelanotide potently activates MC4R Gαq signaling that AgRP cannot efficiently antagonize—a pathway linked in preclinical studies to reduced food intake without cardiovascular pressor effects.